Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06001177CT.gov A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease | — | Completed | — | — | — |
NCT05574010CT.gov A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it) | — | Terminated | — | — | — |
NCT04248855CT.gov Assessment of KAN-101 in Celiac Disease (ACeD) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Celiac Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Kan-101 (this asset) | Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA | P2 | BB · 65 |
| Necator Americanus | James Cook University, Queensland, Australia | P2 | BB |
| Macrogols | Sheffield Teaching Hospitals NHS Foundation Trust | P4 | BB |
| Larazotide | 9 Meters Biopharma, Inc. | P3 | BB |
| Latiglutenase | Entero Therapeutics | P2 | BB |
| Prolyl Endopeptidase | Dr. C. Bonorino Udaondo Gastroenterology Hospital | P4 | BB |
| Simvastatin | Entero Therapeutics | P2/3 | BB |
| Vivomixx | University of Milan | P4 | BB |
| Prucalopride | University of British Columbia | P4 | BB |
+42 more in the Celiac Disease cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Kan-101 in Celiac Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/kan-101-celiac-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →